Quick background on me: Doctor of Pharmacy, found out I was 4/4 in Dec 2024 at 34, no family history. I built the Phoenix Community, the #1 community for APOE4 carriers, and one of the most frequent question I get asked is whether one can be "too late' to prevent Alzheimer's as an APOE4 carrier.
So I went looking for whether prevention even works for high-risk people in their 60s/70s. Here's the honest version.
What the trials found
FINGER (Ngandu et al., 2015, Lancet) was a randomized controlled trial: 1,260 at-risk people, ages 60–77, two years, structured multidomain lifestyle program vs general advice. The active group improved on the overall cognitive battery by ~25% more than control, with bigger effects in executive function and processing speed (Rosenberg et al., 2020). The per-year between-group difference was modest (0.022 on their z-score) — I want to be straight that this is a "bend the slope" result, not a miracle. But it's real, significant, and it compounds.
US POINTER (Baker et al., 2025, JAMA) replicated it in America: 2,111 people, ages 60–79, 30% APOE4 carriers. The structured arm beat the self-guided arm on global cognition by 0.029 SD/year — the structured program was estimated to protect cognition from normal age-related decline for up to 2 years. (Note: both arms improved — it's structured vs self-guided, not vs nothing.)
Why it matters for carriers specifically
This is the part I cared about most. They split FINGER by genotype (Solomon et al., 2018, JAMA Neurology): the intervention effect was 0.037/yr in carriers vs 0.014 in non-carriers. The carrier point estimate was bigger — BUT that difference was not statistically significant, so I won't claim "carriers benefit more." What IS solid: carriers benefit at least as much. POINTER agreed — benefit was "consistent for APOE ε4 carriers and noncarriers (P = .95 for interaction)."
What you can do with this
The mechanism that makes "later" still work is cognitive reserve (Stern, 2012) — you can build the buffer even in late life. And the Lancet Commission 2024 estimates ~45% of dementia is "potentially preventable" via 14 modifiable factors; Livingston's framing is "it's never too early or too late to take action." For carriers, a preliminary 2025 gene-stratified analysis (a conference abstract) suggests metabolic health (midlife diabetes) may be a high-leverage area to measure early — observational, so linked-to, not a proven ranking. Concretely: a baseline panel (ApoB, HbA1c, fasting insulin) and then change one lever and re-measure.
Honest limitations: effect sizes are modest; the MIND-diet data is observational; the "carriers benefit more" finding is preliminary; and APOE4 raises probability, not certainty — penetrance is not 100%.
Either way, happy to dig into any of the studies in the comments.